Biogen Inc.

NASDAQ:BIIB

Drug Manufacturers - General

Healthcare
$251.41 -1.11%

-$2.21 today

Market cap
$37.16B
Beta
0.18
P/E (TTM)
21.1
EPS (TTM)
$9.32
52W Low $121.05High $205.97

Volume 1.14M

Average 1.17M

BIIB Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Biogen Inc.NASDAQ: BIIB

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to 3.6%

Net margin was 3.6% in Q2 FY2026, down 20.4 pp from a year earlier. On a trailing-twelve-month basis it was 8.4%, down 6.9 pp year over year. Over 3 fiscal years it narrowed by 16.8 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 26 analysts of 17.5% for the fiscal year ending Dec 2026, up from 13.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
3.6%-9.3 pp QoQ
Last fiscal yearDec 2025
13.2%-3.7 pp YoY
LTMJun 2026
8.4%-6.9 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-20.4 pp-7.8 pp+12.6 pp
1 year-3.7 pp+4.4 pp+8.0 pp
3 years-16.8 pp+11.2 pp+28.0 pp
5 years+12.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
13.2%
Year-over-year change
-3.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How BIIB compares with its peers on the latest reported figures

  • BIIB's LTM Jun 2026 net margin of 8.4% is the 8th highest of the 11 companies compared; the peer median is 20.3%.
  • Its year-over-year change of -6.9 pp is the 8th highest of 11, against a peer median of +0.2 pp.
  • Over three fiscal years its change of -16.8 pp compares with a peer median of +5.0 pp.
BIIB Competitors Peer median
Net Margin for BIIB and competitors
Company Period LTM level YoY 3-year change
UTHRUnited Therapeutics CorporationLTM Jun 202641.6% +1.2 pp+4.4 pp
LLYEli Lilly and CompanyLTM Jun 202633.5% +7.6 pp+9.8 pp
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 202630.6% -0.7 pp-4.5 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202627.9% -3.5 pp-4.2 pp
AMGNAmgen Inc.LTM Jun 202622.9% +4.0 pp-3.9 pp
AZNAstraZeneca PLCLTM Sep 202617.7% +1.5 pp+10.0 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202616.8% +29.8 pp+117.5 pp
BIIBBiogen Inc.LTM Jun 20268.4% -6.9 pp-16.8 pp
PFEPfizer Inc.LTM Jun 20266.8% -10.0 pp-18.6 pp
PTCTPTC Therapeutics, Inc.LTM Jun 2026-3.8% -39.5 pp+119.4 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-56.9% -30.4 pp+5.6 pp
Peer median (excluding BIIB) 20.3%+0.2 pp+5.0 pp

Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.98B10.17B9.84B9.68B9.81B
Cost of Revenue2.11B2.28B2.53B2.31B2.9B
Gross Profit8.87B7.9B7.3B7.37B6.91B
Gross Margin80.8%77.6%74.2%76.1%70.5%
Research & Development3.4B2.6B2.7B2.49B1.95B
Selling, General & Admin2.68B2.41B2.5B2.39B2.43B
Operating Expenses6.08B5.01B5.2B4.88B5.04B
Depreciation & Amortization487.7M518.4M494.8M673.2M779.9M
EBITDA3.92B3.54B2.38B3B2.95B
EBITDA Margin35.7%34.8%24.2%31.0%30.0%
Operating Income2.79B2.89B2.1B2.49B1.88B
Operating Margin25.4%28.4%21.3%25.7%19.1%
Interest Income11M89.3M276.5M67.6M87.8M
Interest Expense253.6M246.6M246.9M250.3M246M
Other Income / Expenses(1.01B)705.3M(800.5M)(584.3M)(476M)
Income Before Tax1.78B3.59B1.3B1.91B1.4B
Pre-Tax Margin16.2%35.3%13.2%19.7%14.3%
Income Tax Expense52.5M632.8M135.3M273.8M108.11M
Net Income1.56B3.05B1.16B1.63B1.29B
Net Margin14.2%29.9%11.8%16.9%13.2%
EPS (Basic)10.4420.978.0211.208.85
EPS (Diluted)10.4020.877.9711.198.83
Weighted Avg Shares149.1M145.3M144.7M145.7M146.7M
Weighted Avg Shares (Diluted)149.6M146M145.6M145.9M146.7M

Biogen Inc.

NASDAQ:BIIB

Intrinsic Alpha fair value

Locked

Current Price

$251.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.